Amendments to the Claims:

This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Original) A compound of general formula (I):

$$X_3$$
 $(X_4X_4'C)_q$
 X_5
 X_5
 X_5
 X_5
 X_5
 X_5
 X_5
 X_5
 X_5
 X_1
 X_1
 X_2
 X_2
 X_1
 X_2
 X_3

wherein R_1 and R_2 are independently selected from the group consisting of hydrogen, optionally substituted alkyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇ and -(Y)_mC=(Z)(T)_n-, optionally substituted alkenyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇ and -(Y)_mC=(Z)(T)_n-, optionally substituted aralkyl which may be interrupted within the alkyl moiety by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇ and -(Y)_mC=(Z)(T)_n-, optionally substituted heterocyclic, optionally substituted aryl, optionally substituted acyl and a carbohydrate moiety;

or R_1 and R_2 together with the nitrogen atom from which they depend form a saturated or unsaturated, optionally substituted heterocyclic group which may include additional heteroatoms selected from the group consisting of O, N and S;

A is selected from the group consisting of O, S, SO, SO₂, Se, Te, NR₈, CR₉R'₉, N->O and C(O);

 $X_1 \text{ is selected from the group consisting of } OR_3, SR_3, NR_3R'_3, hydrogen, \\ halogen, -(Y)_mC=(Z)(T)_nR_3, -N(C=(Z)(T)_nR_3)_2, N_3, CN, OCN, SCN, OSO_3R_3, OSO_2R_3, \\ OPO_3R_3R'_3, OPO_2R_3R'_3, S(O)R_3, S(O)_2R_3, S(O)_2OR_3, PO_3R_3R'_3, NR_3NR'_3R''_3, SNR_3R'_3, \\ NR_3R'_3, OPO_2R_3R'_3, S(O)R_3, S(O)_2R_3, S(O)_2OR_3, PO_3R_3R'_3, NR_3NR'_3R''_3, SNR_3R'_3, \\ NR_3R'_3, OPO_2R_3R'_3, S(O)R_3, S(O)_2R_3, S(O)_2OR_3, PO_3R_3R'_3, NR_3NR'_3R''_3, SNR_3R'_3, \\ NR_3R'_3, NR_3R'_3, NR_3R'_3, NR_3R'_3, SNR_3R'_3, SNR_3R^2, SNR$

2

TRII\622682v1

 $NR_3SR'_3$, SSR_3 and R_3 , or is an oxo group, =S, =NOR₃ or =CR₃R'₃ and X₁' is absent, or X₁ is C=(Z) and R₂ is bonded thereto so as to form a cyclic moiety -C=(Z)NR₁S(O)_p-;

 $X_2 \text{ is selected from the group consisting of } OR_4, SR_4, NR_4R'_4, hydrogen, \\ halogen, -(Y)_mC=(Z)(T)_nR_4, -N(C=(Z)(T)_nR_4)_2, N_3, CN, OCN, SCN, OSO_3R_4, OSO_2R_4, \\ OPO_3R_4R'_4, OPO_2R_4R'_4, S(O)R_4, S(O)_2R_4, S(O)_2OR_4, PO_3R_4R'_4, NR_4NR'_4R''_4, SNR_4R'_4, \\ NR_4SR'_4, SSR_4 \text{ and } R_4, \text{ or is an oxo group, } =S, =NOR_4 \text{ or } =CR_4R'_4 \text{ and } X_2' \text{ is absent;}$

 X_3 and X_3 'are independently selected from the group consisting of OR_5 , SR_5 , NR_5R_5 , hydrogen, halogen, $-(Y)_mC=(Z)(T)_nR_5$, $-N(C=(Z)(T)_nR_5)_2$, N_3 , CN, OCN, SCN, OSO_3R_5 , OSO_2R_5 , $OPO_3R_5R_5$, $OPO_2R_5R_5$, $S(O)_2R_5$, $S(O)_2R_5$, $S(O)_2OR_5$, $PO_3R_5R_5$, $NR_5NR_5R_5$, NR_5R_5 , NR_5SR_5 , NR_5SR_5 , NR_5SR_5 , and NR_5 , or NR_5R_5 , NR_5R_5

 $X_4 \text{ is selected from the group consisting of } OR_6, SR_6, NR_6R'_6, hydrogen, \\ halogen, -(Y)_mC=(Z)(T)_nR_6, -N(C=(Z)(T)_nR_6)_2, N_3, CN, OCN, SCN, OSO_3R_6, OSO_2R_6, \\ OPO_3R_6R'_6, OPO_2R_6R'_6, S(O)_2R_6, S(O)_2OR_6, PO_3R_6R'_6, NR_6NR'_6R''_6, SNR_6R'_6, \\ NR_6SR'_6, SSR_6 \text{ and } R_6, \text{ or is an oxo group, } =S, =NOR_6 \text{ or } =CR_6R'_6 \text{ and } X_4' \text{ is absent;}$

 X_5 is selected from the group consisting of hydrogen, CN, -C=(Z)(T)_nR₁₁, $S(O)_2R_{11}$, $S(O)_2R_{11}$, $S(O)_2R_{11}$, $S(O)_2R_{11}$, $S(O)_2R_{11}$, $S(O)_2R_{11}$, $S(O)_2R_{11}$, optionally substituted alkyl, optionally substituted aralkyl, and optionally substituted acyl;

 X_1' , X_2' , X_4' and X_5' are the same or different and are selected from the group consisting of hydrogen, CN, optionally substituted alkyl, optionally substituted alkaryl, optionally substituted aryl, and optionally substituted acyl;

or one of X_1 and X_2 , X_2 and X_5 ', X_5 ' and A when A contains a carbon or nitrogen atom, X_5 and A when A contains a carbon or nitrogen atom, and X_5 and X_1 together constitute a double bond, or X_5 ' and X_4 or X_3 and X_4 together constitute a double bond, or R_1 and X_1 , R_2 and X_1 , R_1 and X_2 , R_2 and X_2 , R_1 and X_5 , R_2 and X_5 , R_1 and X_5 ', R_2 and X_5 ', X_1 and X_2 , X_2 and X_3 , X_2 and X_4 , X_3 and X_4 , X_1 and X_1 ', X_2 and X_2 ', X_3 and X_3 ' or X_4 and X_4 ' together form part of a ring structure which optionally includes at least one heteroatom selected from O, S and N and is optionally substituted;

m and n are independently zero or one and Y, Z and T are independently selected from the group consisting of O, S, and NR₁₀

p is 1 or 2

q is 0 or 1;

 R_{3} , R'_{3} , R'_{3} , R_{4} , R'_{4} , R'_{4} , R'_{5} , R'_{5} , R'_{5} , R'_{6} , R'_{6} , R'_{7} , R_{8} , R_{9} , R'_{9} , R_{10} , R_{11} and R'_{11} are the same or different and are selected from the group consisting of hydrogen, optionally substituted alkyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇ and $-(Y)_{m}C=(Z)(T)_{n}$, optionally substituted alkenyl which may be interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇ and $-(Y)_{m}C=(Z)(T)_{n}$, optionally substituted aryl, optionally substituted heterocyclic, optionally substituted aralkyl which may be interrupted within the alkyl moiety by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇ and $-(Y)_{m}C=(Z)(T)_{n}$, optionally substituted acyl and a carbohydrate moiety;

with the proviso that at least two of X_1 , X_2 , X_3 and X_4 are other than hydrogen or a group linked to the ring through a carbon-carbon bond; or a pharmaceutically acceptable salt thereof.

- 2. (Original) A compound as claimed in claim 1 wherein one or both of R_1 and R_2 is alkyl.
- 3. (Original) A compound as claimed in claim 2 wherein one or both of R_1 and R_2 is $C_{4\cdot 30}$ alkyl.
- 4. (Original) A compound as claimed in claim 3 wherein one or both of R_1 and R_2 is C_{6-12} alkyl.
- 5. (Original) A compound as claimed in claim 4 wherein one or both of R_1 and R_2 is C_{8-10} alkyl.
- 6. (Original) A compound as claimed in claim 1 wherein one or both or R_1 and R_2 is aralkyl.
- 7. (Original) A compound as claimed in claim 6 wherein one or both R_1 and R_2 is $(CH_2)_r$ Ph where Ph is phenyl and r is an integer in the range 1 to 12 inclusive.

TRI1\622682v1

- 8. (Original) A compound as claimed in claim 1 wherein one or both of R_1 and R_2 is alkyl interrupted by one or more heteroatoms or functional groups selected from the group consisting of O, S, -N=, NR₇, and -(Y)_mC=(Z)(T)_n.
- 9. (Original) A compound as claimed in claim 8 wherein one or both of R_1 and R_2 is alkyl interrupted by one or more oxygen atoms.
- 10. (Original) A compound as claimed in claim 9 wherein one or both of R_1 and R_2 is $CH_3(CH_2)_xO(CH_2)_yO(CH_2)_z$ wherein x is an integer in the range 0 to 12 inclusive and y and z are independently integers in the range 1 to 12 inclusive.
- 11. (Original) A compound as claimed in claim 1 wherein one or both of R_1 and R_2 is alkenyl.
- 12. (Original) A compound as claimed in claim 1 wherein R₁ and R₂ together with the nitrogen atom from which they depend form a saturated or unsaturated heterocyclic group.
- 13. (Original) A compound as claimed in claim 1 wherein R_1 and R_2 together with the nitrogen atom from which they depend form a lactam or cyclic imide.
- 14. (Currently Amended) A compound as claimed in any one of claims claim 1 to 13 wherein q is 1.
- 15. (Currently Amended) A compound as claimed in any one of claims claim 1 to 13 wherein q is 0.
- 16. (Currently Amended) A compound as claimed in any one of claims claim 1 to 15 wherein A is selected from the group consisting of O, S and NR₈.
 - 17. (Original) A compound as claimed in claim 16 wherein A is O.
 - 18. (Currently Amended) A compound as claimed in any one of claims claim 1

5

TRI1\622682v1

to 17 wherein X_1 is OR_3 .

- 19. (Currently Amended) A compound as claimed in claim 18 wherein R₃ is hydrogen, acyl, or optionally substituted acyl.
- 20. (Currently Amended) A compound as claimed in any one of claims claim 1 to 19-wherein X_2 is OR_4 .
- 21. (Currently Amended) A compound as claimed in claim 20 wherein R₄ is hydrogen, acyl, or optionally substituted acyl.
- 22. (Currently Amended) A compound as claimed in any one of claims claim 1 to 21 wherein X_3 is OR_5 .
- 23. (Currently Amended) A compound as claimed in claim 22 wherein R_5 is hydrogen, acyl, or optionally substituted acyl.
- 24. (Currently Amended) A compound as claimed in any one of claims claim 1 to 14 and 16 to 23 wherein X₄ is OR₆.
- 25. (Currently Amended) A compound as claimed in claim 24 wherein R₆ is hydrogen, acyl, or optionally substituted acyl.
- 26. (Currently Amended) A compound as claimed in any one of claims claim 1 to 25 wherein p is 1.
- 27. (Currently Amended) A compound as claimed in-any one of claims claim 1 to 25 wherein p is 2.
 - 28. (Currently Amended) A compound selected from the group consisting of: *N*,*N*-dibutyl-*S*-(2,3,5,6-tetra-*O*-benzoyl-β-D-galactofuranosyl)sulfonamide *N*,*N*-dihexyl-*S*-(2,3,5,6-tetra-*O*-acetyl-β-D-galactofuranosyl)sulfonamide *N*,*N*-dioctyl-*S*-(2,3,5,6-tetra-*O*-benzoyl-β-D-galactofuranosyl)sulfonamide

N,N-didecyl-S-(2,3,5,6-tetra-O-acetyl- β -D-galactofuranosyl)sulfonamide N,N-dibenzyl-S-(2,3,5,6-tetra-O-benzoyl- β -D-galactofuranosyl)sulfonamide N,N-di(2-methoxyethoxyethyl)-S-(2,3,5,6-tetra-O-acetyl- β -D-

galactofuranosyl)sulfonamide

N,N-dioctyl-S-(2,3,5,6-tetra-O-acetyl- β -D-glucofuranosyl)sulfonamide N,N-dioctyl-S-(2,3-di-O-acetyl-5-O-[tert-butyldiphenylsilyl]- α -D-arabinofuranosyl)sulfonamide

N,N-dibutyl-S-(β-D-galactofuranosyl)sulfonamide

N,N-dihexyl-S-(β-D-galactofuranosyl)sulfonamide

N.N-dioctyl-S-(β-D-galactofuranosyl)sulfonamide

N,N-didecyl-S-(β-D-galactofuranosyl)sulfonamide

N,N-dibenzyl-S-(β-D-galactofuranosyl)sulfonamide

N,N-di(2-methoxyethyl)-S-(β -D-galactofuranosyl)sulfonamide and

N,N-dioctyl-S-(β-D-glucofuranosyl)sulfonamide.

29. (Original) A method of preparation of a compound of general formula (I)

$$X_3$$
 X_2
 X_2
 X_3
 X_4
 X_4
 X_5
 X_5

comprising reacting a compound of general formula (II):

$$X_3$$
 X_2 X_2 X_1 X_1 X_2 X_2 X_1 X_2 X_2 X_1 X_2 X_2 X_2 X_3 X_2 X_3 X_2 X_3 X_2 X_3 X_4 X_5 X_5

wherein R_1 , R_2 , A, p, q, X_1 , X_1 , X_2 , X_2 , X_3 , X_3 , X_4 , X_4 , X_4 , X_5 and X_5 are as defined above; with an oxidising agent.

30. (Currently Amended) A method for the treatment of a microbial infection

TRI1\622682v1 7

Attorney Docket No.: 012930-000029 Preliminary Amendment for new US Appln under Rule 371 Priority to Int'l Appln PCT/AU2004/001110

comprising administering to a patient in need of such treatment a therapeutically effective amount of a compound of general formula (I) as claimed in any one of claims claim 1-to 28.

- 31. (Currently Amended) A method for the manufacture of a medicament for The use of in the treatment of a microbial infection comprising making a medicament containing a compound of general formula (I) as claimed in any one of claims claim 1 to 28 in the manufacture of a medicament for use in the treatment of a microbial infection.
- 32. (Currently Amended) A pharmaceutical composition comprising a compound of general formula (I) as claimed in any one of claims claim 1 to 28 and a pharmaceutically acceptable carrier.
- 33. (Currently Amended) A method of killing a microorganism, comprising exposing said microorganism to a compound of general formula (I) as claimed in any one of claims claim 1-to 28.

8

TRI1\622682v1